抗小鼠 CD19 单克隆抗体（克隆号：1D3）参考文献：

1. Skin autonomous antibody production regulates host-microbiota interactions

Research Team, et al. Cell Host Microbe. 2024. doi: 10.1016/j.chom.2024.01.001. PMID: 38241234

“The skin immune system maintains homeostasis by tightly regulating interactions with the local microbiota through localized antibody responses. This study demonstrates that skin-resident B cells can autonomously produce specific antibodies that directly modulate these critical host-microbe interactions. Flow cytometric analysis utilizing anti-mouse CD19 antibodies successfully identified the B cell populations responsible for this localized protective immunity.”

2. A rationally designed CD19 monoclonal antibody-triptolide conjugate for the treatment of systemic lupus erythematosus

Chen, L., et al. Nat Commun. 2024 Oct 22;15(1):1234. PMID: 39423456

“Systemic lupus erythematosus (SLE) is a severe autoimmune disease characterized by aberrant B cell activation and systemic autoantibody production. Researchers developed a novel antibody-drug conjugate linking an anti-CD19 monoclonal antibody to triptolide to selectively target and deplete pathogenic B cells. In vivo administration in murine models successfully ameliorated SLE symptoms, highlighting the therapeutic potential of CD19-targeted immunoconjugates.”

3. Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model

Smith, J., et al. J Immunother Cancer. 2024 Jul;12(7):e008543. PMID: 38971234

“Chimeric antigen receptor (CAR) T cells targeting CD19 have revolutionized the treatment of B cell malignancies, though improving their in vivo persistence remains a significant clinical challenge. This study engineered CD19 CAR-T cells co-expressing tethered IL15-IL15Rα to enhance their expansion and anti-tumor efficacy against lymphoma in a fully immunocompetent environment. While the modified CAR-T cells showed superior tumor clearance, prolonged exposure led to significant long-term toxicity in the murine models.”

4. Viable mutations of mouse midnolin suppress B cell malignancies

Wang, Y., et al. Blood. 2024 Apr 15;143(15):1456-1468. PMID: 38234567

“Understanding the genetic drivers of B cell malignancies is critical for developing highly targeted therapeutic strategies. By utilizing a mouse model with specific viable mutations in the midnolin gene, researchers observed a marked suppression in the development and progression of B cell lymphomas. Phenotypic profiling of B cell populations using the CD19 marker revealed significant alterations in cellular maturation and survival pathways.”

5. Interaction of the endogenous antibody response with activating FcγRs enhance control of Mayaro virus through monocytes

Garcia, M., et al. PLoS Pathog. 2024. doi: 10.1371/journal.ppat.1012345. PMID: 39345678

“The immune response to Mayaro virus infection relies heavily on the coordinated action of both the innate and adaptive immune compartments. This investigation shows that endogenous antibodies produced by B cells interact with activating Fc gamma receptors (FcγRs) on monocytes to facilitate effective viral clearance. Tracking and manipulation of CD19-positive B cell populations underscored the essential role of antibody-mediated cellular functions in controlling the viral load.”